| SCHEDULE OF BASIC AND DILUTED NET INCOME (LOSS) PER SHARE OF COMMON STOCK |
The
following table reflects the calculation of basic net income (loss) per share of Common Stock (in dollars, except share amounts):
SCHEDULE OF BASIC AND DILUTED NET INCOME (LOSS) PER SHARE OF COMMON STOCK
| | |
Three Months Ended | | |
Three Months Ended | |
| | |
March 31, 2026 | | |
March 31, 2025 | |
| Basic and diluted net loss per Common Stock | |
| | | |
| | |
| Numerator: | |
| | | |
| | |
| Net loss | |
$ | (1,930,884 | ) | |
$ | (2,902,828 | ) |
| Denominator: | |
| | | |
| | |
| Basic and diluted weighted average Common Stock outstanding | |
| 148,000,149 | | |
| 2,322,772 | |
| Basic and diluted net loss per Common Stock | |
$ | (0.01 | ) | |
$ | (1.25 | ) |
| | |
Nine Months Ended | | |
Nine Months Ended | |
| | |
March 31, 2026 | | |
March 31, 2025 | |
| Basic net income per Common Stock | |
| | | |
| | |
| Numerator: | |
| | | |
| | |
| Net income | |
$ | 4,412,993 | | |
$ | 7,425,515 | |
| Denominator: | |
| | | |
| | |
| Basic weighted average Common Stock outstanding | |
| 116,647,478 | | |
| 975,727 | |
| Basic net income per Common Stock | |
$ | 0.04 | | |
$ | 7.61 | |
The
following table reflects the calculation of diluted net income (loss) per share of Common Stock (in dollars, except share amounts):
| | |
Nine Months Ended- | | |
Nine Months Ended- | |
| | |
March 31, 2026 | | |
March 31, 2025 | |
| Diluted net income per Common Stock | |
| | | |
| | |
| Numerator: | |
| | | |
| | |
| Net income | |
$ | 4,412,993 | | |
$ | 7,425,515 | |
| Change in fair value of financial instruments | |
| 1,073,373 | | |
| (13,979,733 | ) |
| Interest on dilutive instruments | |
| 1,587,348 | | |
| 6,050,871 | |
| Allocation of net income, as adjusted | |
$ | 7,073,714 | | |
$ | (503,347 | ) |
| Denominator: | |
| | | |
| | |
| Dilutive weighted average Common Stock outstanding | |
| 116,647,478 | | |
| 975,727 | |
| If converted shares | |
| 19,698,961 | | |
| — | |
| Dilutive weighted average Common Stock outstanding | |
| 136,346,439 | | |
| 975,727 | |
| Diluted net income per Common Stock | |
$ | 0.05 | | |
$ | (0.52 | ) |
|
| SCHEDULE OF DILUTIVE INSTRUMENTS |
Below
is a summary of the potentially dilutive instruments as of March 31, 2026 and 2025:
SCHEDULE OF DILUTIVE INSTRUMENTS
| Description | |
March 31, 2026 | | |
March 31, 2025 | |
| Sellers Notes | |
| — | | |
| 13,214,028 | |
| Convertible notes - Chardan | |
| — | | |
| 1,594,763 | |
| Secured convertible note | |
| 14,169,724 | | |
| 11,333,505 | |
| Winston & Strawn agreement | |
| — | | |
| 1,034,381 | |
| Tau agreement | |
| — | | |
| 888,973 | |
| Debenture | |
| 3,555,553 | | |
| — | |
| Unissued Stock Based compensation shares | |
| 1,973,684 | | |
| — | |
| Promissory note | |
| — | | |
| 6,040 | |
| Total Shares issuable under Convertible Note obligations – if converted total dilutive | |
| 19,698,961 | | |
| 28,071,690 | |
| | |
| | | |
| | |
| Public Warrants | |
| 10,062,500 | | |
| 10,062,500 | |
| Private Warrants | |
| 5,553,125 | | |
| 5,553,125 | |
| 2025 Warrants | |
| 16,258,332 | | |
| — | |
| Secured convertible note warrants | |
| 600,000 | | |
| 600,000 | |
| Total excluded under treasury method – out of the money | |
| 32,473,957 | | |
| 16,215,625 | |
|